Rechercher des projets européens

34 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine (MultipleMS)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations.MultipleMS will therefor ...
Voir le projet

 25

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet

 44

 TERMINÉ 

European Gram Negative Antibacterial Engine (ENABLE)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Voir le projet

 42

 TERMINÉ 

Imaging the Force of Cancer (FORCE)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat ...
Voir le projet

 18

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras ...
Voir le projet

 40

 TERMINÉ 

Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT)

Date du début: 1 juil. 2014, Date de fin: 30 juin 2019,

The current healthcare systems are built around the traditional paradigm of patients suffering from a single acute illness. They are therefore largely unprepared to face the increasing demands for health services arising from the expansion of an older population with specific medical needs related to multiple chronic disorders. As a consequence, the medical conditions of a large and growing seg ...
Voir le projet

 27

 TERMINÉ 

Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has ...
Voir le projet

 29

 TERMINÉ 

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy (AETIONOMY)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2018,

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerativ ...
Voir le projet

 20

 TERMINÉ 

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)

Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,

The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet

 26

 TERMINÉ 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Voir le projet

 28

 TERMINÉ 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Voir le projet

 22

 TERMINÉ 

Kinetics for Drug Discovery (K4DD) (K4DD)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,

There is mounting evidence that the often ignored kinetic aspects of the interaction between a drug and its target are highly relevant for clinical success. This ignorance may be one of the reasons for the high attrition rates in drug discovery, as it has been analyzed that many recently marketed drugs had indeed improved kinetic profiles. This hindsight knowledge needs to be converted into data-d ...
Voir le projet

 21

 TERMINÉ 

Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)

Date du début: 1 mai 2012, Date de fin: 30 oct. 2017,

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Voir le projet

 23

 TERMINÉ 

Oral biopharmaceutics tools (ORBITO)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel propsective studies to define new methodlogies which will be validated using historical datasets from EFPIA partners. A combination of high quality in vitro or in silico characterizations of API and formulations will ...
Voir le projet

 28

 TERMINÉ 

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE (DRIVE-AB)

Date du début: 1 oct. 2014, Date de fin: 30 sept. 2017,

Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements ...
Voir le projet

 27

 TERMINÉ 

Delivering European Translational Information & Knowledge Management Services (ETRIKS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

Since its inception the IMI has funded over 30 public-private partnership projects. Many of these projects are centered upon data intensive translational research and are employing integrative analysis approaches to achieve their goals. Although a common KM platform for IMI projects was envisioned in the original IMI Strategic Research Agenda it has not yet been implemented. The lack of a common p ...
Voir le projet

 17

 TERMINÉ 

Recognising Adverse Drug Reactions (WEB-RADR)

Date du début: 1 sept. 2014, Date de fin: 31 août 2017,

WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Voir le projet

 20

 TERMINÉ 

New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier (TRANS-INT)

Date du début: 1 mai 2012, Date de fin: 30 avr. 2017,

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improveme ...
Voir le projet

 20

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Voir le projet

 29

 TERMINÉ 

Infection biology training network: shaping the future of infectious diseases treatments (INBIONET)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

...s internationally recognized in the fields of microbial pathogenesis, innate immunity and molecular recognition, an intensive research SME, Preclin Biosystems, a multinational pharmaceutical company, Sanofi-Aventis, and a technological park (ParcBit). INBIONET partners will embark on the analysis of bacteria, viruses and enteric parasites specified by various infection strategies to identify cellu ...
Voir le projet

 11

 TERMINÉ 

Incorporating real-life clinical data into drug development (GETREAL)

Date du début: 1 oct. 2013, Date de fin: 31 déc. 2016,

When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and efficacy of the medicine in a clinical trial setting. However, assessing the expected future value of the medicines when used in “real world” clinical practice requires additional information next to traditional (pre-authorisation) clinical trials. Regulatory, HTA ...
Voir le projet

 32

 TERMINÉ 

Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,

The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet

 30

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

Development of RApid Point-of-Care test Platforms for Infectious Diseases (RAPP-ID)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2016,

RAPP-ID (“Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hospital
Voir le projet

 20

 TERMINÉ 

European Medicines Research Training Network (EMTRAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2016,

EMTRAIN is an essential element for the success of the IMI Education & Training (E&T) Call Topics in Europe (current and future). It will establish a pan-European platform of excellence for education and training covering the whole life-cycle of medicines from basic research through clinical development to pharmaco-vigilance. It will underpin the successful delivery of the current and future IMI-f ...
Voir le projet

 32

 TERMINÉ 

European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)

Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,

The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Voir le projet

 24

 TERMINÉ 

Electronic Health Record systems for Clinical Research (EHR4CR)

Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,

Current medical needs, the growth of targeted therapies and personalized medicines, and escalating R&D costs result in formidable cost pressures on healthcare systems and the pharmaceutical industry. Clinical research is also growing in complexity, labour intensity and cost. There is a growing realization that the development and integration of Electronic Health Record systems (EHRs) for medical ...
Voir le projet

 37

 TERMINÉ 

Novel nanoparticles for drug delivery to the skin (NANODRUG)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,

The aim of the NANODRUG Network is to contribute to the defragmentation of the emerging field of nanomedicine by providing a unique training programme that will cover all different aspects ranging from NP synthesis and characterisation, drug delivery, molecular biology to nanotoxicology, preclinical studies, risk assessment and nanotechnology policy making. The NANODRUG training program is far sup ...
Voir le projet

 9

 TERMINÉ 

Understanding chronic pain and improving its treatment (EUROPAIN)

Date du début: 1 oct. 2009, Date de fin: 30 sept. 2015,

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Re ...
Voir le projet

 29

 TERMINÉ 

SAFER AND FASTER EVIDENCE-BASED TRANSLATION (SAFE-T)

Date du début: 15 juin 2009, Date de fin: 14 juin 2015,

The public-private consortium composed of complementary SMEs, academic and clinical centers of excellence and EMEA as partner proposes SAFE-T (Safer And Easter Evidence-based Iranslation) project for the establishment of a biomarker (BM) qualification process and its validation in clinical biomarker studies designed for the translation, performance testing and eventual regulatory qualifIcatIon of ...
Voir le projet

 26

 TERMINÉ 

Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)

Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,

Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet

 36

 TERMINÉ 

Pharmaceutical Medicine Training Programme (PHARMATRAIN)

Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,

"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet

 52

 TERMINÉ 

Light-based functional in vivo monitoring of diseases related enzymes (LIVIMODE)

Date du début: 1 nov. 2009, Date de fin: 30 avr. 2013,

"LIVIMODE aims to develop specific tools for non invasive in vivo imaging of disease related molecular events. Such tools are of high relevance for disease detection, staging, developing animal models of human disease, and evaluating novel therapies. We propose to use optical imaging, which is optimally suited for this task as it provides excellent sensitivity and allows visualizing molecular even ...
Voir le projet

 13